Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
23 hedge funds and large institutions have $19.5M invested in Achilles Therapeutics in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13.96% less ownership
Funds ownership: 66.88% → 52.92% (-14%)
18% less funds holding
Funds holding: 28 → 23 (-5)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
42% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 12
68% less capital invested
Capital invested by funds: $61.6M → $19.5M (-$42.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$680K |
| 2 |
Millennium Management
New York
|
+$138K |
| 3 |
Jane Street
New York
|
+$76.3K |
| 4 |
CF
Cantor Fitzgerald
New York
|
+$67.3K |
| 5 |
VF
Virtu Financial
New York
|
+$52.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.74M |
| 2 |
O
OrbiMed
New York
|
-$3.31M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.17M |
| 4 |
KHCM
Kettle Hill Capital Management
New York
|
-$844K |
| 5 |
BlackRock
New York
|
-$572K |
ACHL Hedge Fund Activity: Q4 2022 in Review
23 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q4 2022, worth a combined $19.5M — down 68% from $61.6M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ACHL and 7 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $680K. The largest seller was RA Capital Management, cutting an estimated $5.74M.
- 23 institutional investors held Achilles Therapeutics (ACHL) as of Q4 2022, down from 28 in Q3 2022.
- Funds reported $19.5M of Achilles Therapeutics stock for Q4 2022, down 68% quarter-over-quarter.
- 7 funds opened new Achilles Therapeutics positions in Q4 2022 and 12 closed out, a net change of -5 holders.
- The largest Achilles Therapeutics buyer in Q4 2022 was Renaissance Technologies, an estimated $680K added.
- The largest Achilles Therapeutics seller in Q4 2022 was RA Capital Management, an estimated $5.74M sold.
Based on aggregated 13F filings for Q4 2022.